5-PGDH expression in breast cancer cells

This paper analyzes 15-PGDH gene expression in the human breast cancer (BC) cell liness and describes the molecular principles through which the expression of the enzyme 15-PGDH is controlled in the tumor cells with a varying metastatic potential. There is an inverse correla- tion of 15-PGDH gene expression with COX-2 expression and the metastatic potential of tumor cells. Investigation of mechanisms for 15-PGDH regulation opens up new vistas and possibilities for the design of effective drugs for the targeted therapy of metastatic forms of BC.

breast cancer, COX-1, COX-2, 15-PGDH, predictive marker for breast cancer, COX-2 inhibitors, PGE2, MCF-7, BT-474, and ZR-75-1 human breast tumor cell lines, targeted therapy goal

1. Аксель Е.М., Давыдов М.И. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2008 г. Вестн РОНЦ 2010;21(2 прил 1):52–86.

2. Greenlee R.T., Murray T., Bolden S., Wingo P.A. Cancer statistics, 2000. CA Cancer J Clin 2000;50(1):7–33.

3. Lin F., Luo J., Gao W. et al. COX-2 pro- motes breast cancer cell radioresistance via p38/MAPK-mediated cellular anti-apoptosis and invasiveness. Tumour Biol 2013;34(5):2817–26.

4. Wolf I., O'Kelly J., Rubinek T. et al. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 2006;66(15):7818–23.

5. Zhang B., Ma X., Li Z. et al. Celecoxib en- hances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer. J Cancer Res Clin Oncol 2013;139(5):797–807.

6. Lehtinen L., Vainio P., Wikman H. et al. 15-Hydroxyprostaglandin dehydrogenase as- sociates with poor prognosis in breast cancer, induces epithelial-mesenchymal transition, and promotes cell migration in cultured breast cancer cells. J Pathol 2012;226(4):674–86.

7. Johnson R.F., Mitchell C.M., Clifton V., Zakar T. Regulation of 15-hydroxyprostaglan- din dehydrogenase (PGDH) gene activity, messenger ribonucleic acid processing, and protein abundance in the human chorion

8. in late gestation and labor. J Clin Endocrinol Metab 2004;89(11):5639–48.

9. Bai J.W., Wang Z., Gui S.B., Zhang Y.Z. Loss of 15-hydroxyprostaglandin dehydroge- nase indicates a tumor suppressor role in pitu- itary adenomas. Oncol Rep 2012;28(2):714–20.

10. Miyoshi J., Yajima T., Shimamura K. et al. 5-aminosalicylic acid mediates expression of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase to suppress colorectal tumori- genesis. Anticancer Res 2012;32(4):1193–202. 10. Gonzalez-Villasana V., Gutiérrez-Puente Y., Tari A.M. Cyclooxygenase-2 utilizes Jun N- terminal kinases to induce invasion, but not tamoxifen resistance, in MCF-7 breast cancer cells. Oncol Rep 2013;30(3):1506–10.

11. Ashok V., Dash C., Rohan T.E. et al. Selec- tive cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast 2011;20(1):66–70. 12. Cho M.H., Yoon J.H., Jaegal Y.J. et al. Ex- pression of cyclooxygenase-2 in breast carcino- genesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcino- ma. Breast 2006;15(3):390–8.

12. Choi D., Piao Y.L., Wu Y., Cho H. Control of the intracellular levels of prostaglandin E2 through inhibition of the 15-hydroxyprosta- glandin dehydrogenase for wound healing. Bioorg Med Chem 2013;21(15):4477–84.

13. Lu D., Han C., Wu T. 15-hydroxyprosta- glandin dehydrogenase-derived 15-keto-prosta- glandin E2 Inhibits cholangiocarcinoma cell growth through interaction with peroxisome proliferator-activated receptor- , SMAD2/3, and TAP63 proteins. J Biol Chem 2013;288(27):19484–502.

14. Wakimoto N., Wolf I., Yin D. et al. Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase. Cancer Res 2008;68(17): 6978–86.

15. Subbaramaiah K., Howe L.R., Zhou X.K. et al. Pioglitazone, a PPAR agonist, suppresses CYP19 transcription: evidence for involvement of 15-hydroxyprostaglandin dehydrogenase and BRCA1. Cancer Prev Res (Phila) 2012;5(10):1183–94.

16. Zhang B., Ma X., Li Z. et al. Celecoxib en- hances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer. J Cancer Res Clin Oncol 2013;139(5):797–807.

17. Lou L.H., Jing D.D., Lai Y.X. et al. 15-PGDH is reduced and induces apoptosis and cell cycle arrest in gastric carcinoma. World J Gastroenterol 2012;18(10):1028–37. 19. Wolf I., O'Kelly J., Rubinek T. et al. 15 hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 2006;66(15):7818–23.

18. Na H.K., Park J.M., Lee H.G. et al. 15-Hydroxyprostaglandin dehydrogenase as a novel molecular target for cancer chemoprevention and therapy. Biochem Pharmacol 2011;82(10):1352–60.

19. Roberts H.R., Smartt H.J., Greenhough A. et al. Colon tumour cells increase PGE(2) by regulating COX-2 and 15-PGDH to promote survival during the microenvironmental stress of glucose deprivation. Carcinogenesis 2011;32(11):1741–7.

20. Thill M., Fischer D., Kelling K. et al. Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH2)D3) and prostaglandin E2 (PGE2) serum level in ovarian cancer patients.

21. J Steroid Biochem Mol Biol 2010; 121(1–2):387–90.

22. Moore A.E., Greenhough A., Roberts H.R. et al. HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells. Carcinogenesis 2009;30(10):1796–804.

23. Cordes T., Hoellen F., Dittmer C. et al. Correlation of prostaglandin metabolizing enzymes and serum PGE2 levels with vitamin D receptor and serum 25(OH)2D3 levels in breast and ovarian cancer. Anticancer Res 2012;32(1): 351–7.

24. Lehtinen L., Vainio P., Wikman H. et al. 15-Hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer, induces epithelial-mesenchymal transition, and promotes cell migration in cultured breast cancer cells. J Pathol 2012;226(4):

25. –86.